Here are four points:
1. The funds will be used to advance commercialization of the company’s two-gene blood test for post-surgical monitoring of colorectal cancer recurrence.
2. The blood test aims to detect tumor-specific methylated DNA biomarkers that leak from active lesions into the circulatory system.
3. The financing is being led by OneVentures, a venture capital firm.
4. Paul Kelly, MD, partner and managing director of OneVentures, will join Clinical Genomics’ board of directors in connection with the financing.
More articles on GI/endoscopy:
Stay ahead of the quality-reporting game: Leverage data to maximize outcomes & reimbursement
Boston Scientific launches AXIOS Stent, EndoGastric Solutions presents promising 3-year TIF data — 6 GI company key notes
El Camino Hospital launches 1st GutCheck System trial: 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.